Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.
Parirenyatwa Group of Hospitals, Harare, Zimbabwe
Harare Central Hospital, Harare, Zimbabwe
Sports Surgery Clinic, Santry, Dublin, Ireland
Spine Care Orthopedics - NYU Lagone Medical Center, New York, New York, United States
Memorial Orthopaedic Surgery Group, Long Beach, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
University Hospitals Leuven, Leuven, Belgium
Box Hill Hospital, Box Hill, Victoria, Australia
Monash Medical Centre, Clayton, Victoria, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Hamilton General Hospital, Hamilton, Ontario, Canada
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States
University of Texas - Houston, Houston, Texas, United States
WSUPG Dermatology, Dearborn, Michigan, United States
Albany Medical Center, Albany, New York, United States
Keçiören Training and Research Hospital, Ankara, Turkey
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.